Spotlight

Vice-Provost's View: Farewell UCL

It has been a great privilege to be Vice-Provost (Enterprise) at UCL and inevitably as I pack my bags to make the long trip from Gordon Street to the Wellcome Trust on Euston Road, I have been reflecting on the last five years. So much has changed and so much has been achieved by UCL.

Read more



follow us on twitter


Helicon Health: Putting patients first

A pharmacist for 26 years with a PhD in Health Informatics, Bridget Coleman took on a new challenge when she signed up for the KEA (Knowledge Exchange Associate) programme at UCL Advances. Bridget works with the anticoagulation and stroke prevention services at the Whittington Hospital in London, looking at treatments for conditions caused by blood clots.

Gene Therapy at UCL: a powerful new way to treat haemophilia A

A long-awaited breakthrough occurred in February 2013, when UCL Business (UCLB) signed a licensing agreement with US biotechnology firm Biomarin to develop a new Factor VIII gene therapy programme. The agreement came after a 2011 trial in which the Royal Free London NHS Foundation Trust reported that six people with haemophilia B saw a reduction in symptoms after gene therapy on liver cells. This breakthrough might pave the way for potentially curative life-saving treatment to become widely available.

UCL Consultants Award 2014: Professor Gordon Blunn and Professor Alister Hart

 Prof Gordon Blunn & Prof Alister Hart
 UCL Consultants Award 2014

UCL Business Award 2014: Professor Amit Nathwani

 Prof Amit Nathwani
 UCL Business Award 2014